Intercept to Announce First Quarter 2018 Financial Results on May 8, 2018 and Present at Upcoming Investor Conferences
Intercept management will also be presenting at the following upcoming investor conferences:
Deutsche Bank43rd Annual Health Care Conferenceat 9:20 a.m. ETon Wednesday, May 9, 2018 Bank of America Merrill Lynch2018 Healthcare Conference at 5:00 p.m. PTon Tuesday, May 15, 2018 UBS Global Healthcare Conferenceat 3:00 p.m. ETon Monday, May 21, 2018 Jefferies2018 Global Healthcare Conference at 9:00 a.m. ETon Friday, June 8, 2018
Webcast information for these events will be available on the investor page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in
For more information about
Media inquiries: firstname.lastname@example.org
Source: Intercept Pharmaceuticals, Inc.